TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32565122

Group type: EXPERIMENTAL
Intervention: 1% THC dose of cannabis
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 4% THC dose of cannabis
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 7% THC dose of cannabis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: THC plasma levels between 16 ng/mL and 31 ng/mL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cognitive tests
Number of subjects: 16
Study: 36092192

Group type: EXPERIMENTAL
Intervention: Intralesional MMR (0.3 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subcutaneous MMR (0.5 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 33039134

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study: 36308239

Group type: EXPERIMENTAL
Intervention: Manual K‐files
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Manual H‐files
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Kedo‐S Square rotary files
Number of subjects: 45
Study: 32503030

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (unexposed to aminophylline)
Number of subjects: 16
Study: 32220551

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 535

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 535
Study: 34783998

Group type: EXPERIMENTAL
Intervention: Video-assisted self-reflection during resuscitation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Self-reflection alone (control group)
Number of subjects: 10
Study: 33909172

Group type: EXPERIMENTAL
Intervention: Reduced dose glucocorticoids (GC) for induction and maintenance of remission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) combined with cyclophosphamide (CYC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepolizumab (interleukin-5 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative immunosuppressive agents (e.g. mycophenolate mofetil, abatacept)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged course of maintenance treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 0
Study: 32928579

Group type: EXPERIMENTAL
Intervention: Whey protein, leucine, and vitamin D supplementation for 12 weeks (Supp group, n=28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Dietary counseling for ordinary protein-rich diet (Diet group, n=28)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (Supp and Diet)
Number of subjects: 56
Study: 32196748

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (10g/d increase)
Number of subjects: 0
Study: 36397118

Group type: EXPERIMENTAL
Intervention: Amino acid blend
Number of subjects: 35
Study: 32192596

Group type: EXPERIMENTAL
Intervention: Gonadotropin, clomiphene, or letrozole with IUI for four or fewer treatment cycles
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Clinical androgen markers
Number of subjects: 900
Study: 33858493

Group type: EXPERIMENTAL
Intervention: Standard of care plus investigational treatment (IT) with cisternal lavage using urokinase, nimodipine, and Ringer’s solution
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 54
Study: 35441700

Group type: EXPERIMENTAL
Intervention: Online Healthwise® Driving Decision Aid (DDA)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control (web-based information for older drivers)
Number of subjects: 301
Study: 34383536

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 95
Study: 32302056

Group type: EXPERIMENTAL
Intervention: 10 mg dose of macitentan (film‐coated adult formulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10 mg dose of macitentan (two 5 mg dispersible tablets pediatric formulation)
Number of subjects: 12
Study: 36480373

Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion-based intervention (MCBI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Active control group (empathy diary)
Number of subjects: 63
Study: 33274859

Group type: EXPERIMENTAL
Intervention: 5‐FU@AICRM with green light irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group without green light irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carmofur (CF, a hydrophobic analog of 5‐FU)‐loaded AICRM (CF@AICRM)
Number of subjects: 0
Study: 32899135

Group type: EXPERIMENTAL
Intervention: Intervention group (school-based obesity prevention program implemented over two years)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intervention group (school-based obesity prevention program)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 33982418

Group type: EXPERIMENTAL
Intervention: Finely milled 30 mg ER tablets (EDR 6.9)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coarsely milled 30 mg ER tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finely milled 80 mg ER tablets (EDR 4.9)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finely milled IR tablets
Number of subjects: 0
Study: 33174525

Group type: EXPERIMENTAL
Intervention: 3D-precise breast conformer (3D-BCT group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual compensator (ST group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No compensator (NST group)
Number of subjects: 30
Study: 36175907

Group type: EXPERIMENTAL
Intervention: HIIT exercise group
Number of subjects: 52

Group type: COMPARATOR
Intervention: UC group
Number of subjects: 52
Study: 33755051

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) at cut-off values of 2 μg/g
Number of subjects: 9822

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) at cut-off values of 10 μg/g
Number of subjects: 9822

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT) at cut-off values of 150 μg/g
Number of subjects: 9822
Study: 32207414

Group type: COMPARATOR
Intervention: Cervical manual therapy alone (Control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cervical along with thoracic manual therapy (Experimental)
Number of subjects: 37
Study: 35707040

Group type: EXPERIMENTAL
Intervention: PiCCO monitoring
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 34607147

Group type: EXPERIMENTAL
Intervention: Light intensity at 10 lux
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Light intensity at 30 lux
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Light intensity at 50 lux
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Lohmann Brown‐Lite (LB)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Lohmann LSL‐Lite (LW)
Number of subjects: 1800
Study: 36341464

Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccination
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Protein/peptide vaccines
Number of subjects: 117

Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 117

Group type: COMPARATOR
Intervention: Single group assignment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Phase 1 trials
Number of subjects: 117

Group type: COMPARATOR
Intervention: Funding sources
Number of subjects: 117

Group type: COMPARATOR
Intervention: Geographic location
Number of subjects: 117

Group type: COMPARATOR
Intervention: Trial outcomes
Number of subjects: 117
Study: 35557088

Group type: EXPERIMENTAL
Intervention: ACTH infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 33096392

Group type: EXPERIMENTAL
Intervention: Tocolysis
Number of subjects: 46

Group type: COMPARATOR
Intervention: No tocolysis (Control)
Number of subjects: 46
Study: 35809011

Group type: EXPERIMENTAL
Intervention: Social interaction intervention (visit with a person with a new ostomy)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 51
Study: 33278626

Group type: EXPERIMENTAL
Intervention: Nurse-led, goal-directed lung physiotherapy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard therapy for sepsis
Number of subjects: 201
Study: 34698353

Group type: EXPERIMENTAL
Intervention: Chlormadinone
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 32321477

Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Number of subjects: 60
Study: 35179551

Group type: EXPERIMENTAL
Intervention: Ivermectin (0.4 mg/kg body weight daily for 5 days) + standard of care
Number of subjects: 490

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 490
Study: 32117545

Group type: COMPARATOR
Intervention: Standard Ponseti casting technique (once-weekly)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Accelerated Ponseti casting technique (twice-weekly)
Number of subjects: 100
Study: 35904872

Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis (VRH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 34127852

Group type: EXPERIMENTAL
Intervention: Danuglipron (PF-06882961)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 32656934

Group type: EXPERIMENTAL
Intervention: Real-time PCR followed by high-resolution melting analysis (HRMA)
Number of subjects: 232
Study: 36089068

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 32063564

Group type: EXPERIMENTAL
Intervention: L‐Carnosine 400 mg twice daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: L‐Carnosine
Number of subjects: 58
Study: 32687220

Group type: EXPERIMENTAL
Intervention: Higher empathy after induced happiness
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Lower empathy after induced sadness
Number of subjects: 218

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 218
Study: 33566465

Group type: EXPERIMENTAL
Intervention: Enoxaparin prophylaxis started less than 24 hours after insertion of central venous catheter, adjusted to anti-Xa level of 0.2-0.5 international units/mL
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study: 36108676

Group type: EXPERIMENTAL
Intervention: Vitamin B complex supplementation (thiamine 10 mg, riboflavin 4 mg, nicotinamide 40 mg, dexpanthenol 6 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (similar nutritional supports without group B vitamins)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Vitamin B complex supplementation
Number of subjects: 85
Study: 33239268

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 0
Study: 32645831

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Citrate + Theobromine
Number of subjects: 47
Study: 36125471

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg, n=51)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (n=50)
Number of subjects: 101
Study: 34052685

Group type: EXPERIMENTAL
Intervention: Topiramate (N = 39)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (N = 26)
Number of subjects: 65
Study: 32176321

Group type: EXPERIMENTAL
Intervention: Prass standard monopolar stimulator
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bipolar stimulator
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dissecting instrument
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ball tip stimulator
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pooled mean latency
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pooled mean threshold
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pooled mean saturation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Monopolar electrodes
Number of subjects: 11
Study: 34131878

Group type: EXPERIMENTAL
Intervention: Portal message reminder with self-scheduling option (n=5408)
Number of subjects: 16728

Group type: EXPERIMENTAL
Intervention: Portal message reminder only (n=5699)
Number of subjects: 16728

Group type: COMPARATOR
Intervention: Control group (no portal message) (n=5621)
Number of subjects: 16728

Group type: EXPERIMENTAL
Intervention: Comparison between self-scheduling and message only groups
Number of subjects: 16728
Study: 33548492

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 32178964

Group type: EXPERIMENTAL
Intervention: Atezolizumab (840 mg) plus nab-paclitaxel (100 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel (100 mg/m2)
Number of subjects: 0
Study: 35675795

Group type: EXPERIMENTAL
Intervention: AO + PES
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BCI-AO + continuous PES
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: BCI-AO + triggered PES
Number of subjects: 34

Group type: COMPARATOR
Intervention: AO alone
Number of subjects: 34
Study: 32822325

Group type: EXPERIMENTAL
Intervention: Conventional yoghurt (300 grams daily for 8 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Organic yoghurt (300 grams daily for 8 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (Conventional and Organic yoghurt)
Number of subjects: 37
Study: 36283011

Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control (historical group)
Number of subjects: 203
Study: 34018637

Group type: COMPARATOR
Intervention: Prognostic Nutritional Index (PNI)
Number of subjects: 5839
Study: 32077305

Group type: EXPERIMENTAL
Intervention: Social Branding intervention in bars and nightclubs (anti-tobacco messages through events, opinion leaders, art, direct mail, promotional activities, online media)
Number of subjects: 7240

Group type: EXPERIMENTAL
Intervention: Social Branding intervention in bars and nightclubs
Number of subjects: 7240

Group type: COMPARATOR
Intervention: Control group (Los Angeles)
Number of subjects: 7240

Group type: EXPERIMENTAL
Intervention: Social Branding intervention
Number of subjects: 7240
Study: 35786577

Group type: EXPERIMENTAL
Intervention: Endosequence Bioceramic Sealer (BCS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: AH Plus (AHP)
Number of subjects: 64
Study: 34138761

Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 42

Group type: COMPARATOR
Intervention: sham-taVNS
Number of subjects: 42
Study: 32727707

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 49

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baseline soluble mesothelin-related peptide
Number of subjects: 49
Study: 34254218

Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (AEG, n = 11) performing aerobic exercise on an adapted exercise bike three times a week for three months (36 sessions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance exercise group (REG, n = 14) performing resistance exercise using elastic bands and ankle cuffs three times a week for six months (72 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG, n = 9 for AEG and n = 12 for REG)
Number of subjects: 20
Study: 34571336

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (with initial stable disease at week 12)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (with initial stable disease at week 12 followed by subsequent response)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (with initial stable disease at week 12 followed by no change in response or progression)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (with initial stable disease at week 12 followed by progression before week 24)
Number of subjects: 294
Study: 34388424

Group type: EXPERIMENTAL
Intervention: HV night splint (SP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise (EX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-voltage galvanic stimulation (HVPGS) (EL)
Number of subjects: 60
Study: 35299084

Group type: EXPERIMENTAL
Intervention: FeZnPM (iron- and zinc-biofortified pearl millet)
Number of subjects: 223

Group type: COMPARATOR
Intervention: CPM (conventional non-biofortified pearl millet)
Number of subjects: 223
Study: 32236404

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 45
Study: 33328044

Group type: EXPERIMENTAL
Intervention: dCBT-I
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Patient education
Number of subjects: 1721
Study: 34524565

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 114
Study: 33079754

Group type: EXPERIMENTAL
Intervention: Auricular percutaneous electrical nerve field stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 35125129

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 703
Study: 34073134

Group type: EXPERIMENTAL
Intervention: Heat exposure (35 °C)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (19 °C)
Number of subjects: 22
Study: 32000674

Group type: EXPERIMENTAL
Intervention: Double-space technique (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single-space technique (n=20)
Number of subjects: 40
Study: 33508756

Group type: EXPERIMENTAL
Intervention: Synthetic screening mammography (SM) plus digital breast tomosynthesis (DBT)
Number of subjects: 1206
Study: 34318568

Group type: EXPERIMENTAL
Intervention: Structured short intervention consisting of self-reflection, education on skin diseases, contact with a person with psoriasis, and case studies.
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group attending regular lessons.
Number of subjects: 221
Study: 35983682

Group type: EXPERIMENTAL
Intervention: Educational intervention + low-cost water filter pitcher
Number of subjects: 0

Group type: COMPARATOR
Intervention: Only the filter
Number of subjects: 0
Study: 33902816

Group type: EXPERIMENTAL
Intervention: Nonverbal response card arm
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Conventional verbal response arm
Number of subjects: 1644
Study: 35388626

Group type: EXPERIMENTAL
Intervention: High-frequency oscillation (HFO)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 319
Study: 34874887

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (UCG)
Number of subjects: 50
Study: 34102253

Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant (fulvestrant 500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1; ribociclib 600 mg/day, 3 weeks on, 1 week off)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (fulvestrant 500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant (first-line setting)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (first-line setting)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant (second-line setting)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (second-line setting)
Number of subjects: 726
Study: 36352146

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Surgeon's choice of surgery
Number of subjects: 376
Study: 34152420

Group type: EXPERIMENTAL
Intervention: Active VR
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Passive VR
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 90
Study: 32182916

Group type: EXPERIMENTAL
Intervention: PSA_MSA algorithm (combination of pixel-swapping algorithm and modified simulated annealing algorithm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSA_MSA algorithm
Number of subjects: 0
Study: 36401728

Group type: EXPERIMENTAL
Intervention: Melatonin plus standard treatment
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 226
Study: 34362490

Group type: COMPARATOR
Intervention: Serum adenosine deaminase (ADA) levels in AL patients
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Serum ADA correlation with Hcy, ALT, AST, GGT, LDH in AML group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Serum ADA correlation with GGT in ALL group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for ADA in AML group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for ADA in ALL group
Number of subjects: 123
Study: 36078602

Group type: EXPERIMENTAL
Intervention: Acupressure wristband at P6 point applied three times daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Regular doses of intravenous antiemetics
Number of subjects: 90
Study: 34270335

Group type: EXPERIMENTAL
Intervention: Ultrarapid lispro (URLi)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lispro (Humalog®)
Number of subjects: 42
Study: 32619713

Group type: EXPERIMENTAL
Intervention: Group 1: 660 nm, 15 mW, 3.8 J/cm2, starting on the first day of radiotherapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Group 2: 660 nm, 25 mW, 6.3 J/cm2, starting on the first day of radiotherapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Group 3: 660 nm, 15 mW, 3.8 J/cm2 for therapeutic purpose
Number of subjects: 73
Study: 34396485

Group type: EXPERIMENTAL
Intervention: Mini implants in conjunction with class II elastics
Number of subjects: 28

Group type: COMPARATOR
Intervention: Class II elastics therapy (control group)
Number of subjects: 28
Study: 34569426

Group type: EXPERIMENTAL
Intervention: 100 IU HBIG + HBVac
Number of subjects: 331

Group type: COMPARATOR
Intervention: 200 IU HBIG + HBVac
Number of subjects: 331
Study: 34266402

Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy alone (51 Gy in 17 fractions + boost of 15 Gy in 5 fractions)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Combined modality treatment (Photon IMRT 50 Gy in 25 fractions + boost using 8 × 3 Gy carbon ions)
Number of subjects: 314